Lionel Noy
Hematology & Oncology · Doral, FLNPI 1780672097
Payments from drug & device makers
Across 127 payments — averaging $74.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Avyxa Pharma, LLC$3K
- Johnson & Johnson$1K
- Pharmacyclics LLC, An Abbvie Company$715
- E.r. Squibb & Sons, L.L.C.$681
- Bristol Myers Squibb$451
- Incyte Corporation$418
- plus $3K from 16 others
What the payments were for
- Speaking & faculty fees$2,00021%
- Travel & lodging$8049%
- Food & beverage$6,03964%
- Education$5656%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Avyxa Pharma, LLC | 4 | $2,992 |
| Johnson & Johnson(2 entities) | 18 | $1,408 |
| Pharmacyclics LLC, An Abbvie Company | 22 | $715 |
| E.r. Squibb & Sons, L.L.C. | 11 | $681 |
| Bristol Myers Squibb | 17 | $451 |
| Incyte Corporation | 5 | $418 |
| AstraZeneca | 4 | $379 |
| AbbVie | 8 | $367 |
| Clovis Oncology, Inc. | 9 | $320 |
| Merck | 3 | $274 |
| Regeneron Healthcare Solutions, Inc. | 2 | $244 |
| Lilly USA, LLC | 3 | $219 |
| Beigene USA, Inc. | 3 | $156 |
| Eisai Inc. | 2 | $145 |
| EMD Serono, Inc. | 1 | $122 |
| Novartis | 7 | $120 |
| Rigel Pharmaceuticals, Inc. | 1 | $109 |
| Janssen Scientific Affairs, LLC | 1 | $104 |
| Blue Earth Diagnostics | 1 | $90 |
| Daiichi Sankyo Inc. | 2 | $39 |
| Pfizer | 2 | $37 |
| Amgen | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,408 in reported general payments places this provider in the 45th percentile of 694 hematology & oncology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 17 | $294,731 |
| JakafiRuxolitinib Phosphate | 13 | $205,340 |
| IbrancePalbociclib | 12 | $190,830 |
| Abiraterone Acetate | 31 | $2,482 |
| Exemestane | 65 | $1,157 |
| Fentanyl | 25 | $678 |
| Folic Acid | 431 | $510 |
| Dexamethasone | 85 | $430 |
| Imatinib Mesylate | 15 | $379 |
| Bicalutamide | 51 | $326 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 21 | $264 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 40 | $263 |
| Hydroxyurea | 46 | $256 |
| Prednisone | 77 | $175 |
| Anastrozole | 54 | $167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $379 | $294,73117 claims |
| Incyte CorporationJakafi | $418 | $205,34013 claims |
| PfizerIbrance | $37 | $190,83012 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $104 | $2,48231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Doral
- Carl LandgrenMiami$47.8M
- Julio ChavezTampa$16.4M
- Steven AttiaJacksonville$13.9M
- Santosh NairOrange City$13.5M
- Frederick LockeTampa$12.8M
- Tarek MekhailOrlando$11.2M
- Carlos AlemanyOrlando$10.9M
- Thomas GeorgeGainesville$10.3M
- Sikander AilawadhiJacksonville$9.8M
- Richard KimTampa$8.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.